THE LONG SFA LESION SOLUTION

GORE VIABAHN® ENDOPROSTHESIS

PERFORMANCE
through data

Only the GORE® VIABAHN® Endoprosthesis covers diseased and irregular tissue of the arterial wall

- GORE® VIABAHN® Endoprosthesis
  - — Patency is independent of lesion length in several studies [1–6]
  - — In the Gore VIPER Clinical Study, no difference in primary patency between lesions > = 20 cm and < 20 cm (p = 0.51) [6]
  - — Fracture is rare even in long SFA lesions [7]
- Bare Nitinol Stents
  - — Patency is dependent on lesion length and severity in several studies [10–17]
  - — In Durability II study, primary patency was 81.3% in < 8 cm lesions and 55.8% in > 8 cm lesions [17]
  - — 31% fracture rate at one year in long SFA lesions[7]; stent fracture may affect device primary patency [8, 9]

The GORE® VIABAHN® Endoprosthesis exhibits proven performance in long, challenging SFA lesions



Prospective Randomized or Prospective Multi-Center (> 2 sites) SFA studies included [1, 2, 6, 7, 18–27]. Registry studies not included. Patency definitions may vary. P value indicates result of t-test on slope of linear regression compared to zero.

Long SFA Lesion Treatment with Three Year Follow-up



Figure 1. Original CTO (32 cm)



Figure 2. Post – GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface Placement*



Figure 3. Three Year Follow-up

Images courtesy of Barry Weinstock, MD.

Figure 1. Patient with 32 cm long CTO with lifestyle limiting claudication and hematologic disorder.

Figure 2. Patient treated with 7 x 15, 7 x 15 and 7 x 10 GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface. Post-procedure angiogram confirms good device sizing at proximal and distal landing zones. Around two and a half years, antiplatelet and anegrelide were discontinued for a surgery and the stent grafts thrombosed. This was resolved by thrombolysis and the additional implant of a stent graft proximal to the original GORE® VIABAHN® Devices.

Figure 3. Devices are widely patent at three years.

* The GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface is known in some markets as the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface.

References

1. Saxon RR, Dake MD, Volgelzang RL, Katzen BT, Becker GJ. Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. *Journal of Vascular & Interventional Radiology* 2008;19(6):823-832.
2. McQuade K, Gable D, Pearl G, Theune B, Black S. Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. *Journal of Vascular Surgery* 2010;52(3):584-591.
3. Jahnke T, Andresen R, Müller-Hülsbeck S, *et al*. Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial. *Journal of Vascular & Interventional Radiology* 2003;14(1):41-51.
4. Bray PJ, Robson WJ, Bray AE. Percutaneous treatment of long superficial femoral artery occlusive disease: efficacy of the Hemobahn Stent-Graft. *Journal of Endovascular Therapy* 2003;10(3):619-628.
5. Fischer M, Schwabe C, Schulte K-L. Value of the Hemobahn/Viabahn Endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. *Journal of Endovascular Therapy* 2006;13(6):281-290.
6. VIPER: heparin-coated Viabahn with contoured edge exhibits improved patency in the SFA at one year. vascularNEWS International 2011;51:2. http://www.cxvascular.com/vn-latest-news/vascular-news---latest-news/heparin-coated-viabahn-with-contoured-edge-exhibits-improved-patency-in-the-sfa-at-one-year . Published November 3, 2011. Accessed November 4, 2011.
7. Ansel GM. 1-year interim results from the VIBRANT (Viabahn Versus Bare-Nitinol Stent) study of the Gore Viabahn endoprosthesis. Presented at Vascular Interventional Advances (VIVA) Annual Meeting; Oct. 20-23, 2009; Las Vegas, NV.
8. Scheinert D, Scheinert S, Sax J, *et al*. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. *Journal of the American College of Cardiology* 2005;45(2):312-315.
9. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Nagata S. Influence of stent fracture on the long-term patency in the femoro-popliteal artery. JACC : *Cardiovascular Interventions* 2009;2(7):665-671.
10. Dosluoglu HH, Cherr GS, Lall P, Harris LM, Dryjski ML. Stenting vs above knee polytetrafluoroethylene bypass for TransAtlantic Inter-Society Consensus-II C and D superficial femoral artery disease. *Journal of Vascular Surgery* 2008;48(5):1166-1174.
11. Surowiec SM, Davies MG, Eberly SW, *et al*. Percutaneous angioplasty and stenting of the superficial femoral artery. *Journal of Vascular Surgery* 2005;41(2):269-278.
12. Ihnat DM, Duong ST, Taylor ZC, *et al*. Contemporary outcomes after superficial femoral artery angioplasty and stenting: the influence of TASC classification and runoff score. *Journal of Vascular Surgery* 2008;47(5):967-974.
13. Gur I, Lee W, Akopian G, Rowe VL, Weaver FA, Katz SG. Clinical outcomes and implications of failed infrainguinal endovascular stents. *Journal of Vascular Surgery* 2011;53(3):658-666.
14. Soga Y, Iida O, Hirano K, Yokoi H, Nanto S, Nobuyoshi M. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. *Journal of Vascular Surgery* 2010;52(3):608-615.
15. Suzuki K, Iida O, Soga Y, et al. Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry. *Circulation Journal* 2011;75(4):939-944.
16. Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. *Journal of Vascular Surgery* 2009;50(3):542-547.
17. EverFlex™ Self-Expanding Peripheral Stent System. Plymouth, MN: Covidien; 2012. [Product brochure] 115661-001(A).
18. Laird JR, Katzen BT, Scheinert D, *et al*; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. *Circulation: Cardiovascular Interventions* 2010;3(3):267-276.
19. Zeller T, Tiefenbacher C, Steinkamp HJ. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformexx Trial (FACT). *Journal of Endovascular Therapy* 2008;15(4):390-398.
20. Matsumura J; DURABILITY II Investigators. Durability II. Full data set at 12 months. Presented at the International Symposium on Endovascular Therapy (ISET); January 15-19, 2012; Miami Beach, FL.
21. Krankenberg H, Schlüter M, Steinkamp HJ, *et al*. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length. The Femoral Artery Stenting Trial (FAST). *Circulation* 2007;116(3):285-292.
22. Dake MD, Ansel GM, Jaff MR, *et al*; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. *Circulation: Cardiovascular Interventions 2011*;4(5):495-504.
23. Dick P, Wallner H, Sabeti S. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. *Catheterization & Cardiovascular Interventions* 2009;74(7):1090-1095.
24. Schillinger M, Sabeti S, Dick P, *et al*. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. *Circulation* 2007;115(21):2745-2749.
25. Sabeti S, Czerwenka-Wenkstetten A, Dick P, *et al*. Quality of life after balloon angioplasty versus stent implantation in the superficial femoral artery: findings from a randomized controlled trial. *Journal of Endovascular Therapy* 2007;14(4):431-437.
26. Duda SH; SUPER-SL Investigators. The SUPER-SL Study. Multi-center, head-to-head comparison of the S.M.A.R.T.® CONTROL Nitinol Stent (Cordis®) with the Luminexx 6F Stent (Bard®) for the treatment of long TASC C & D superficial femoral artery lesions. Presented at the Leipzig Interventional Course (LINC); January 13-17, 2009; Leipzig, Germany.
27. Lammer J, Dake MD, Bleyn J, *et al*. Peripheral arterial obstruction: prospective study of treatment with a transluminally placed self-expanding stent graft. *Radiology* 2000;217(1):95-104.

GORE
Creative Technologies Worldwide

W. L. Gore & Associates, Inc.
Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)
00800.6334.4673 (Europe)
800.437.8181 (United States)
928.779.2771 (United States)

goremedical.com